#USA #Chicago #Ascletis #ASC47 #ASC30

Breakthrough Diabetes Treatment from Ascletis Pharma at ADA

Ascletis Pharma Inc., listed under the ticker HKEX: 1672, will unveil its pioneering research on promising diabetes treatment candidates, ASC30 and ASC47, at the upcoming 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago from June 20-23, 2025. The presentations will showcase preliminary results of both oral GLP-1 receptor agonist ASC30 and ASC47, a muscle-preserving weight loss drug, highlighting their potential impact on obesity management.

Poster Presentation Details

Ascletis will demonstrate its findings through two key poster presentations detailing the efficacy and mechanisms of action of its innovative compounds. The posters will be displayed in Hall F1:

1. Poster Number 750-P

Title: ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity — A First-in-Human Single Ascending Dose Study
Session Type: General Poster Session
Presentation Time: June 22, 2025, 12:30 PM - 1:30 PM (Chicago Time)

2. Poster Number 847-P

Title: ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model
Session Type: General Poster Session
Presentation Time: June 22, 2025, 12:30 PM - 1:30 PM (Chicago Time)

Understanding ASC30 and ASC47

ASC30

ASC30 is an investigational small molecule acting as a GLP-1 receptor (GLP-1R) agonist, specifically designed for oral administration, unlike many of its counterparts that require injections. It has shown unique properties, making it a groundbreaking option for obesity treatment with potential long-term patent protection until 2044.

The dual-route delivery mechanism of ASC30 is expected to enhance patient compliance and satisfaction while delivering effective obesity mitigation.

ASC47

In contrast, ASC47 is a targeted, ultra-long-acting drug designed to promote weight loss while preserving muscle mass. Utilized subcutaneously, ASC47 uniquely concentrates in adipose tissue, optimizing its weight-loss efficacy. Initial data from a Phase Ib trial has been promising, indicating effective results among patients with elevated LDL-C levels. This drug is currently undergoing trials in conjunction with semaglutide, where early signs suggest it may outperform semaglutide alone in efficacy.

The Impact of the American Diabetes Association

The American Diabetes Association, established in 1940, has become a significant advocate for diabetes research and patient care. Its annual Scientific Sessions cultivate groundbreaking research and innovative approaches to diabetes management and treatment. By inviting Ascletis to present these important studies, ADA promotes forward momentum in understanding and combating diabetes worldwide.

Ascletis Pharma: Leading the Charge

Ascletis Pharma is recognized for its commitment to addressing metabolic diseases. With a focus on internal research and development, the company is actively working on various clinical-stage drug candidates concentrated on illnesses caused by metabolic dysfunctions. The upcoming presentations at ADA reaffirm Ascletis’s dedication to providing innovative treatment options in the fields of diabetes and obesity.

Conclusion

As Ascletis prepares to present its findings, the company shines a light on critical advancements in the treatment of obesity and diabetes. The outcomes from both ASC30 and ASC47 could redefine treatment paradigms in these prevalent conditions, demonstrating Ascletis's commitment to innovation in healthcare. For those looking to stay updated on crucial advancements in medical science, the ADA Scientific Sessions promise to deliver essential insights, with Ascletis at the forefront.

For further information, please visit Ascletis’s official website.